全文获取类型
收费全文 | 8813篇 |
免费 | 415篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 167篇 |
妇产科学 | 84篇 |
基础医学 | 1019篇 |
口腔科学 | 137篇 |
临床医学 | 581篇 |
内科学 | 2169篇 |
皮肤病学 | 109篇 |
神经病学 | 641篇 |
特种医学 | 364篇 |
外科学 | 1996篇 |
综合类 | 26篇 |
现状与发展 | 1篇 |
预防医学 | 171篇 |
眼科学 | 112篇 |
药学 | 551篇 |
中国医学 | 8篇 |
肿瘤学 | 1083篇 |
出版年
2023年 | 64篇 |
2022年 | 86篇 |
2021年 | 194篇 |
2020年 | 120篇 |
2019年 | 165篇 |
2018年 | 194篇 |
2017年 | 182篇 |
2016年 | 231篇 |
2015年 | 235篇 |
2014年 | 296篇 |
2013年 | 348篇 |
2012年 | 546篇 |
2011年 | 594篇 |
2010年 | 386篇 |
2009年 | 330篇 |
2008年 | 548篇 |
2007年 | 604篇 |
2006年 | 603篇 |
2005年 | 595篇 |
2004年 | 610篇 |
2003年 | 561篇 |
2002年 | 549篇 |
2001年 | 95篇 |
2000年 | 74篇 |
1999年 | 98篇 |
1998年 | 114篇 |
1997年 | 98篇 |
1996年 | 95篇 |
1995年 | 80篇 |
1994年 | 78篇 |
1993年 | 62篇 |
1992年 | 67篇 |
1991年 | 42篇 |
1990年 | 45篇 |
1989年 | 49篇 |
1988年 | 34篇 |
1987年 | 39篇 |
1986年 | 25篇 |
1985年 | 26篇 |
1984年 | 19篇 |
1983年 | 14篇 |
1982年 | 14篇 |
1981年 | 11篇 |
1980年 | 11篇 |
1979年 | 9篇 |
1978年 | 15篇 |
1969年 | 6篇 |
1968年 | 7篇 |
1967年 | 5篇 |
1966年 | 5篇 |
排序方式: 共有9300条查询结果,搜索用时 31 毫秒
101.
The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. 总被引:4,自引:0,他引:4
102.
Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. 总被引:9,自引:0,他引:9
Shinji Yamamoto Yasuhiko Tomita Yoshihiko Hoshida Shuji Takiguchi Yoshiyuki Fujiwara Takushi Yasuda Masahiko Yano Shoji Nakamori Masato Sakon Morito Monden Katsuyuki Aozasa 《Journal of clinical oncology》2003,21(13):2537-2544
PURPOSE: Valosin-containing protein (VCP; also known as p97) was shown to be associated with antiapoptotic function and metastasis via activation of nuclear factor kappa-B signaling pathway. In this study, association of VCP expression with recurrence of gastric carcinoma (GC), in which lymphatic vessels are the main route of spread, was examined. PATIENTS AND METHODS: VCP expression in 330 patients with GC (242 males and 88 females) with ages ranging from 26 to 81 years (median, 60 years) was analyzed by immunohistochemistry, in which staining intensity in tumor cells was categorized as weaker (level 1) or equal to or stronger (level 2) than that in endothelial cells. RESULTS: Ninety-four (28.7%) patient cases showed level 1 and 233 patient cases (71.3%) showed level 2 VCP expression. Patients with level 2 expression showed higher rates of large tumor size (P <.0001), undifferentiated histologic subtype (P <.05), presence of vascular and lymphatic invasion (P <.0001 for both), presence of lymph node metastasis (P <.0001), deep tumor invasion (P <.0001), and poorer disease-free and overall survivals (P <.0001 for both) compared with those with level 1 VCP expression. Multivariate analysis revealed VCP expression level as an independent prognosticator for disease-free and overall survival. VCP level was an indicator for disease-free and overall survival in the early (pT1; P <.01 and P <.05, respectively) and advanced (pT2-4; P <.05 for both) group of pathologic tumor-node-metastasis system classification. CONCLUSION: The prognostic significance of VCP expression level in GC was demonstrated. 相似文献
103.
Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. 总被引:11,自引:0,他引:11
104.
105.
Treatment of Lethal Midline Granuloma Type Nasal T-Cell Lymphoma 总被引:7,自引:0,他引:7
Kohichi Sakata Masato Hareyama Atushi Ohuchi Mitsuo Sido Hisayasu Nagakura Kazuo Morita Yasuaki Harabuchi Akikatsu Kataura 《Acta oncologica (Stockholm, Sweden)》1997,36(3):307-311
Nasal T-cell lymphoma of the LMG type (LMG-NTL) is characterized by progressive, unrelenting ulceration, and necrosis of the nasal cavity and midline facial tissues. The clinical behavior of this tumor in 16 patients is compared with that of a nasal lymphoma of non-LMG-NTL type (non-LMG-NTL) in 8 patients and a paranasal sinus lymphoma (PSL) in 6 patients. All patients had stage I or II disease. Fourteen of the 16 patients with LMG-NTL received chemotherapy before and/or after radiotherapy. Cause-specific 5-year survival rates for patients with LMG-NTL, non-LMG-NTL, and PSL were 22%, 75%, and 67%, respectively. Seven patients with LMG-NTL, had complete response, although 3 recurred, whereas it was incomplete in 9 patients. The data indicates that it is desirable to deliver 50 Gy or more to achieve in-field control of LMG-NTL. 相似文献
106.
Radiotherapy of Vertebral Hemangiomas 总被引:2,自引:0,他引:2
Koh-Ichi Sakata Masato Hareyama Atushi Oouchi Mitsuo Sido Hisayasu Nagakura Mituharu Tamakawa Hidenari Akiba Kazuo Morita 《Acta oncologica (Stockholm, Sweden)》1997,36(7):719-724
Between 1975 and 1996, 14 patients (11 females, 3 males) with vertebral hemangioma received treatment with radiotherapy. Thirteen patients had a history of back pain or lumbago and 2 patients had neurological symptoms such as sensory impairment or paraplegia. The standard dose administered was 36 Gy in 18 fractions (five treatments per week). In the 13 patients with pain, this was completely or partially relieved. The condition of a man with hypesthesia of the legs deteriorated and a woman with paraplegia who was treated with decompressive laminectomy followed by radiotherapy recovered completely after irradiation. CT scan before irradiation showed thickened trabeculae as small punctate areas of sclerosis in all patients. At MR imaging before irradiation, T2-weighted MR images showed areas of high intensity in all patients and MR images demonstrated lesion enhancement. However, none of the patients who were treated successfully with radiation demonstrated any changes of the affected vertebra in the conventional radiographic films, CT scan or MR imaging, even 5 years after irradiation. Radiological imaging is indispensable for the diagnosis of vertebral hemangiomas but does not appear to be useful for evaluating the effects of radiotherapy. 相似文献
107.
Joyce K James Masato Nakamura Atsuro Nakazato Kanyin E Zhang Merryl Cramer Janice Brunner Jacquelynn Cook Weichao G Chen 《Drug metabolism and disposition》2005,33(9):1373-1381
Metabolism and disposition of MGS0028 [(1R,2S,5S,6S)-2-amino-6-fluoro-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid monohydrate], a potent group II metabotropic glutamate receptor agonist, were examined in three preclinical species (Sprague-Dawley rats, beagle dogs, and rhesus monkeys). In rats, MGS0028 was widely distributed and primarily excreted in urine as parent and as a single reductive metabolite, identified as the 4R-isomer MGS0034 [(1R,2S,4R,5S,6S)-2-amino-6-fluoro-4-hydroxybicyclo[3.1.0]-hexane-2,6-dicarboxylic acid]. MGS0028 had a low brain to plasma ratio at efficacious doses in rats and was eliminated more slowly in rat brain than in plasma. Exposure increased proportionally (1--10 mg/kg p.o.) in rats, with bioavailability>60% at all doses. However, bioavailability was only approximately 20% in monkeys, and MGS0034 was found in relatively high abundance in plasma. In dogs, oral bioavailability was >60%, and the metabolite was not detected. In vitro metabolism was examined in liver subcellular fractions (microsomes and cytosol) from rat, dog, monkey, and human. Reductive metabolism was observed in rat, monkey, and human liver cytosol incubations, but not in dog liver cytosol incubations. No metabolism of MGS0028 was detected in incubations with liver microsomes from any species. Similar to in vivo results, MGS0028 was reduced in cytosol stereospecifically to MGS0034. The rank order of in vitro metabolite formation (monkey > rat approximately human > dog) was in agreement with in vivo observations in rats, dogs, and monkeys. Based on the observation of species difference in reductive metabolism, rat and monkey were recommended to be the preclinical species for further characterization prior to testing in humans. Finally, allometric scaling predicts that human pharmacokinetic parameters would be acceptable for further development. 相似文献
108.
Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. 总被引:4,自引:0,他引:4
Toshiya Chiba Koichi Tokuuye Yasushi Matsuzaki Shinji Sugahara Yoshimichi Chuganji Kenji Kagei Junichi Shoda Masaharu Hata Masato Abei Hiroshi Igaki Naomi Tanaka Yasuyuki Akine 《Clinical cancer research》2005,11(10):3799-3805
PURPOSE: We present results of patients with hepatocellular carcinoma (HCC) treated with proton beam therapy. EXPERIMENTAL DESIGN: We reviewed 162 patients having 192 HCCs treated from November 1985 to July 1998 by proton beam therapy with or without transarterial embolization and percutaneous ethanol injection. The patients in the present series were considered unsuitable for surgery for various reasons, including hepatic dysfunction, multiple tumors, recurrence after surgical resection, and concomitant illnesses. The median total dose of proton irradiation was 72 Gy in 16 fractions over 29 days. RESULTS: The overall survival rate for all of the 162 patients was 23.5% at 5 years. The local control rate at 5 years was 86.9% for all 192 tumors among the 162 patients. The degree of impairment of hepatic functions attributable to coexisting liver cirrhosis and the number of tumors in the liver significantly affected patient survival. For 50 patients having least impaired hepatic functions and a solitary tumor, the survival rate at 5 years was 53.5%. The patients had very few acute reactions to treatments and a few late sequelae during and after the treatments. CONCLUSIONS: Proton beam therapy for patients with HCC is effective, safe, well tolerable, and repeatable. It is the useful treatment mode for either cure or palliation for patients with HCC irrespective of tumor size, tumor location in the liver, insufficient feeding of the tumor with arteries, presence of vascular invasion, impaired hepatic functions, and coexisting intercurrent diseases. 相似文献
109.
110.
Yuhki Koike Keiichi Uchida Mikihiro Inoue Kazuya Ohtsu Takaaki Tanaka Kohei Otake Koji Tanaka Masato Kusunoki 《Pediatrics international》2013,55(3):373-376
A case of sudden cardiopulmonary arrest in a 3‐month‐old girl is presented. The patient had barely recovered from hypoxic encephalopathy when she presented with repeated respiratory distress. Computed tomography and endoscopic analysis revealed a shiny polyp in the lateral wall of the nasopharynx, and this polyp was suspected to be the main cause of respiratory distress. After referral to our hospital, surgical removal was performed, and the histopathological diagnosis was hairy polyp. Hairy polyp is a rare congenital benign tumor that sometimes induces respiratory distress. This polyp can potentially induce a life‐threatening event. In a systematic review of 40 reported cases, polyps of ≤3.0 cm in diameter have a higher risk of respiratory distress than do those >3.0 cm in diameter (P = 0.01). Small hairy polyps may be lethal because of delayed diagnosis. To locate small hairy polyps, physicians should not hesitate to perform further examination because there is the possibility of oversight with only physical examination. 相似文献